{"id":"chlorprothixene","rwe":[],"tags":[{"label":"chlorprothixene","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"DRD4","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"N05AF03","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Schizophrenia","category":"indication"},{"label":"Roche","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":203.382,"date":"","count":63,"signal":"Neuroleptic malignant syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=203)"},{"llr":100.373,"date":"","count":96,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=100)"},{"llr":100.056,"date":"","count":96,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=100)"},{"llr":90.579,"date":"","count":53,"signal":"Intentional overdose","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=91)"},{"llr":86.912,"date":"","count":36,"signal":"Intentional self-injury","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=87)"},{"llr":85.276,"date":"","count":32,"signal":"Extrapyramidal disorder","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=85)"},{"llr":75.605,"date":"","count":35,"signal":"Serotonin syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=76)"},{"llr":69.82,"date":"","count":22,"signal":"Ileus paralytic","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=70)"},{"llr":66.702,"date":"","count":33,"signal":"Restlessness","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=67)"},{"llr":65.17,"date":"","count":25,"signal":"Muscle rigidity","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=65)"},{"llr":51.529,"date":"","count":36,"signal":"Rhabdomyolysis","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=52)"},{"llr":45.457,"date":"","count":14,"signal":"Gastrointestinal necrosis","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=45)"},{"llr":44.905,"date":"","count":18,"signal":"Akathisia","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=45)"},{"llr":40.926,"date":"","count":17,"signal":"Schizophrenia","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=41)"},{"llr":40.721,"date":"","count":30,"signal":"Suicide attempt","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=41)"}],"drugInteractions":[{"url":"/drug/cisapride","drug":"cisapride","action":"Avoid combination","effect":"May interact with Cisapride","source":"DrugCentral","drugSlug":"cisapride"}],"commonSideEffects":[],"contraindications":["Agranulocytosis","Alcohol withdrawal syndrome","Angle-closure glaucoma","Benign prostatic hyperplasia","Breastfeeding (mother)","Carcinoma of female breast","Coma","Disease of blood AND/OR blood-forming organ","Disorder of cardiovascular system","Drug Induced CNS Depression","Epilepsy","Leukopenia","Neuroleptic malignant syndrome","Neutropenic disorder","Parkinsonism","Retention of urine","Senile dementia","Shock","Stupor","Tardive dyskinesia"]},"trials":[],"aliases":[],"company":"Roche","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHLORPROTHIXENE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:19:46.790997+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:19:52.270256+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORPROTHIXENE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:19:52.668021+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1256658/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:19:53.479289+00:00"}},"allNames":"taractan","offLabel":[],"synonyms":["chlorprothixene","chlorprothixen","chlorprotixen","chlorprotixene","chlothixen","chorprothixene","chlorprothixene hydrochloride","chlorprothixene HCl","taractan"],"timeline":[{"date":"1967-06-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Roche)"}],"aiSummary":"Taractan (chlorprothixene) is a small molecule drug developed by Roche, targeting the 5-hydroxytryptamine receptor 2A. It is a chlorprothixene class medication, approved by the FDA in 1967 for the treatment of schizophrenia. As an off-patent medication, there are no active generic manufacturers. Key safety considerations include its 25.8-hour half-life and 41% bioavailability. Taractan is currently owned by Roche.","approvals":[{"date":"1967-06-19","orphan":false,"company":"ROCHE","regulator":"FDA"}],"brandName":"Taractan","ecosystem":[{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"target":"5-hydroxytryptamine receptor 2A","novelty":"Follow-on","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"DRD5","source":"DrugCentral","target":"D(1B) dopamine receptor","protein":"D(1B) dopamine receptor"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"DRD1","source":"DrugCentral","target":"D(1A) dopamine receptor","protein":"D(1A) dopamine receptor"}],"modality":"Small Molecule","drugClass":"chlorprothixene","explanation":"","oneSentence":"","technicalDetail":"Taractan exerts its antipsychotic effects through antagonism of the 5-HT2A receptor, a subtype of serotonin receptor, which is involved in the regulation of dopamine release and other neurotransmitter systems."},"commercial":{"launchDate":"1967","_launchSource":"DrugCentral (FDA 1967-06-19, ROCHE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/623","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHLORPROTHIXENE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORPROTHIXENE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:35:23.441585","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:19:55.399023+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"thiothixene","drugSlug":"thiothixene","fdaApproval":"1967-07-24","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"chlorprothixene","indications":{"approved":[{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"thiothixene","brandName":"thiothixene","genericName":"thiothixene","approvalYear":"1967","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03449485","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Chlorprothixene","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2018-01-02","conditions":["Obesity, Morbid"],"enrollment":12,"completionDate":"2026-12"},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":["Schizophrenia"],"enrollment":174,"completionDate":"2020-08"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"],"enrollment":725489,"completionDate":"2012-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146149","NDDF":"001516","UNII":"9S7OD60EWP","VUID":"4017788","CHEBI":"CHEBI:3651","VANDF":"4017788","INN_ID":"886","RXNORM":"2406","UMLSCUI":"C0008290","chemblId":"CHEMBL1256658","ChEMBL_ID":"CHEMBL908","KEGG_DRUG":"D00790","DRUGBANK_ID":"DB01239","PUBCHEM_CID":"667467","SNOMEDCT_US":"387317000","IUPHAR_LIGAND_ID":"11976","SECONDARY_CAS_RN":"6469-93-8","MESH_DESCRIPTOR_UI":"D002749"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1967-","companyName":"Roche","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"25.8 hours","clearance":"11.5 mL/min/kg","bioavailability":"41%","volumeOfDistribution":"13.7 L/kg"},"publicationCount":434,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AF03","allCodes":["N05AF03"]},"biosimilarFilings":[],"originalDeveloper":"Roche","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"1967","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1967-06-19T00:00:00.000Z","mah":"ROCHE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:19:55.399023+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}